Simcere Pharmaceutical: Net profit in 2025 is expected to increase by approximately 80.1% to 93.9% year-over-year
Simcere Pharmaceutical (02096.HK) announced that, The Group expects to record revenue of approximately RMB7.7 billion to RMB7.8 billion for the fiscal year 2025, representing an increase of approximately 16.0% to 17.6% compared to the revenue of approximately RMB6.635 billion for the year ended December 31, 2024. The Group is expected to record profit attributable to equity holders of the Company of approximately RMB 1.3 billion to RMB 1.4 billion for the fiscal year 2025, representing an increase of approximately 80.1% to 93.9% compared to the restated profit attributable to equity holders of the Company of approximately RMB 722 million for the fiscal year 2024.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Citadel Securities has poached Matthew Zimmerman from Diameter Capital Partners to head investment-grade corporate bond trading.
-
2
What is RCN coin? Where to trade and buy RCN coin?
-
3
What is HNW coin? Where can HNW coin be traded and bought?
-
4
What is BFT token? Can BFT token be held for the long term?
-
5
September Ethereum Price Outlook: Can Polymarket's $2,600 Target Be Achieved?
-
6
How Will BlackRock's Staked Ethereum ETF Impact the Ethereum Ecosystem on Its First Day with $15.5 Million in Inflows?
-
7
What is the value of OLIVE coin? Is OLIVE coin a good long-term investment?
-
8
CNBC: NVIDIA Drops 11% This Week, While AMD, Broadcom, and TSMC Rise
-
9
Chinese stocks led a rally in Asian chip shares as investors shrugged off the NVIDIA controversy surrounding Jensen Huang and rushed back into AI trades.
-
10
Al Jazeera, citing Iranian media: Iranian Navy claims to have shot down US MQ-1 drone in Strait of Hormuz
Markets Today
Recommended Reading





